Suppr超能文献

用于抑制尼帕病毒的法匹拉韦的哌嗪取代衍生物:计算机模拟研究揭示了什么?

Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?

作者信息

Lipin Raju, Dhanabalan Anantha Krishnan, Gunasekaran Krishnasamy, Solomon Rajadurai Vijay

机构信息

Department of Chemistry, Madras Christian College (Autonomous), [affiliated to University of Madras], Tambaram East, Chennai, Tamil Nadu 600 059 India.

CAS in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai, Tamil Nadu 600025 India.

出版信息

SN Appl Sci. 2021;3(1):110. doi: 10.1007/s42452-020-04051-9. Epub 2021 Jan 11.

Abstract

UNLABELLED

Favipiravir is found to show excellent in-vitro inhibition activity against Nipah virus. To explore the structure-property relationship of Favipiravir, in silico designing of a series of piperazine substituted Favipiravir derivatives are attempted and computational screening has been done to evaluate its bimolecular interactions with Nipah virus. The geometrical features of all the molecules have been addressed from Density Functional Theory calculations. Chemical reactivity descriptor analysis was carried out to understand various reactivity parameters. The drug-likeness properties were estimated by a detailed ADMET study. The binding ability and the mode of binding of these derivatives into the Nipah virus are obtained from molecular docking studies. Our calculations show greater binding ability for the designed inhibitors compared to that of the experimentally reported molecule. Overall, the present work proves to offers new insights and guidelines for synthetic chemists to develop new drugs using piperazine substituted Favipiravir in the treatment of Nipah virus.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s42452-020-04051-9.

摘要

未标记

发现法匹拉韦对尼帕病毒显示出优异的体外抑制活性。为了探索法匹拉韦的构效关系,尝试了一系列哌嗪取代的法匹拉韦衍生物的计算机辅助设计,并进行了计算筛选以评估其与尼帕病毒的双分子相互作用。所有分子的几何特征均通过密度泛函理论计算确定。进行了化学反应性描述符分析以了解各种反应性参数。通过详细的ADMET研究评估了类药性质。这些衍生物与尼帕病毒的结合能力和结合模式通过分子对接研究获得。我们的计算表明,与实验报道的分子相比,设计的抑制剂具有更强的结合能力。总体而言,目前的工作为合成化学家开发使用哌嗪取代的法匹拉韦治疗尼帕病毒的新药提供了新的见解和指导方针。

补充信息

在线版本包含可在10.1007/s42452-020-04051-9获取的补充材料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/12b6/7799160/076f90253c80/42452_2020_4051_Sch1_HTML.jpg

相似文献

1
Piperazine-substituted derivatives of favipiravir for Nipah virus inhibition: What do in silico studies unravel?
SN Appl Sci. 2021;3(1):110. doi: 10.1007/s42452-020-04051-9. Epub 2021 Jan 11.
3
Molecular docking, molecular dynamics and binding free energy based identification of novel potential multitarget inhibitors of Nipah virus.
J Biomol Struct Dyn. 2024;42(24):13663-13679. doi: 10.1080/07391102.2023.2277852. Epub 2023 Nov 3.
4
Recuperative potential of Indian medicinal plant compounds- a tool to encumber henipaviruses: an in -silico study.
In Silico Pharmacol. 2024 Aug 2;12(2):72. doi: 10.1007/s40203-024-00236-x. eCollection 2024.
5
Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations.
Chem Zvesti. 2022;76(3):1471-1478. doi: 10.1007/s11696-021-01946-8. Epub 2021 Nov 2.
6
Favipiravir (T-705) protects against Nipah virus infection in the hamster model.
Sci Rep. 2018 May 15;8(1):7604. doi: 10.1038/s41598-018-25780-3.
9
Evaluation of therapeutic potentials of selected phytochemicals against Nipah virus, a multi-dimensional in silico study.
3 Biotech. 2023 Jun;13(6):174. doi: 10.1007/s13205-023-03595-y. Epub 2023 May 10.

引用本文的文献

1
Nipah virus: pathogenesis, genome, diagnosis, and treatment.
Appl Microbiol Biotechnol. 2025 Jul 1;109(1):158. doi: 10.1007/s00253-025-13474-6.
2
Repurposing of approved drugs towards Nipah virus treatment: an in silico docking, molecular dynamics simulation and a MM/GBSA approach.
In Silico Pharmacol. 2025 Jun 13;13(2):86. doi: 10.1007/s40203-025-00371-z. eCollection 2025.
5
Recent Advances of Nipah Virus Disease: Pathobiology to Treatment and Vaccine Advancement.
J Microbiol. 2024 Oct;62(10):811-828. doi: 10.1007/s12275-024-00168-3. Epub 2024 Sep 18.
8
Nipah virus: a potential pandemic agent in the context of the current severe acute respiratory syndrome coronavirus 2 pandemic.
New Microbes New Infect. 2021 May;41:100873. doi: 10.1016/j.nmni.2021.100873. Epub 2021 Mar 19.

本文引用的文献

2
Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice.
Virology. 2020 Jun;545:1-9. doi: 10.1016/j.virol.2020.02.005. Epub 2020 Feb 24.
3
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
Pharmacol Ther. 2020 May;209:107512. doi: 10.1016/j.pharmthera.2020.107512. Epub 2020 Feb 22.
4
Molecular Docking: Shifting Paradigms in Drug Discovery.
Int J Mol Sci. 2019 Sep 4;20(18):4331. doi: 10.3390/ijms20184331.
5
Potential novel inhibitors against emerging zoonotic pathogen : a virtual screening and molecular dynamics approach.
J Biomol Struct Dyn. 2020 Jul;38(11):3225-3234. doi: 10.1080/07391102.2019.1655480. Epub 2019 Aug 22.
6
In Silico Predictions of Endocrine Disruptors Properties.
Endocrinology. 2019 Nov 1;160(11):2709-2716. doi: 10.1210/en.2019-00382.
7
Antivirals targeting the polymerase complex of influenza viruses.
Antiviral Res. 2019 Sep;169:104545. doi: 10.1016/j.antiviral.2019.104545. Epub 2019 Jun 25.
8
9
Computational Identification of Inhibitors Using QSAR Approach Against Nipah Virus.
Front Pharmacol. 2019 Feb 12;10:71. doi: 10.3389/fphar.2019.00071. eCollection 2019.
10
Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing.
J Virol. 2019 Jan 4;93(2). doi: 10.1128/JVI.01217-18. Print 2019 Jan 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验